Meta-Analysis of Efficacy and Safety of Intravenous Iron in Patients With Iron Deficiency and Heart Failure With Reduced Ejection Fraction

Hamza, Mohammad; Sattar, Yasar; Manasrah, Nouraldeen; Patel, Neel N.; Rashdi, Amna; Khanal, Resha; Naveed, Hamza; Zafar, Maha; Khan, Ahsan; Alharbi, Ahoud; Aamir, Muhammad; Gonuguntla, Karthik; Raina, Sameer; Balla, Sudarshan

doi:10.1016/j.amjcard.2023.06.066

Cited by 2 publications

(1 citation statement)

References 36 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…As a result, ID and IDA serve as independent causes of a plethora of health outcomes; additionally, as comorbidities, they can worsen the prognosis and the disease burden in conditions such as congestive heart failure (CHF), chronic kidney disease (CKD), inflammatory conditions, and cancer. ID and IDA have also been reported to increase the risks of hospitalization and death, affect maternal and fetal pregnancy outcomes, and interfere with neurocognitive development among children; preoperative anemia and ID are also recognized as contributory factors in postoperative mortality and morbidity [4][5][6][7][8][9]. Finally, ID and IDA, even in the absence of disease, are known to impair physical exercise performance and reduce quality of life (QoL).…”

Section: Introductionmentioning

confidence: 99%

The Efficacy, Safety, and Economic Outcomes of Using Ferric Derisomaltose for the Management of Iron Deficiency in China: A Rapid Health Technology Assessment

Yun,

YuMei,

et al. 2023

Cureus

View full text Add to dashboard Cite

Intravenous (IV) iron supplementation is the preferred treatment option for managing severe iron deficiency (ID) and ID anemia (IDA). Three of the available IV iron preparations are ferric derisomaltose (FDI), ferric carboxymaltose (FCM), and iron sucrose (IS). The objective of the present work was to review the published literature about the efficacy, safety, quality of life (QoL), and economic outcomes of using FDI, FCM, and IS for the treatment of ID. A systematic literature search was performed following Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines. Eligible studies were assessed for quality using appropriate tools, and data were extracted and analyzed for key outcomes. The evidence synthesis was based on published systematic literature reviews (SLRs), meta-analyses (MAs), indirect treatment comparisons (ITCs), and health technology assessments (HTAs); we also included economic evaluations performed from a Chinese perspective. Out of 337 initial hits, the review included 12 studies. The findings indicated that FDI, FCM, and IS had comparable efficacy in terms of hemoglobin (Hb) improvement. FDI showed a better safety profile with a lower risk of hypophosphatemia, hypersensitivity reactions, and cardiovascular adverse events (AEs) compared to IS and FCM. FDI also demonstrated better cost-effectiveness compared to IS, with potential cost savings attributed to fewer infusions and improved compliance. None of the included studies evaluated QoL after IV iron administration for ID. FDI offers a safe, efficacious, and cost-effective treatment option for ID. It exhibits comparable efficacy to FCM and IS but presents a better safety profile and economic advantage. FDI fulfills the criteria of efficacy, safety, economy, innovation, suitability, and accessibility, making it a promising choice for ID management in China.

show abstract